BioCentury
ARTICLE | Company News

Allergan ophthalmic news

June 29, 2015 7:00 AM UTC

Allergan filed suit against Ferrum Ferro Capital in the U.S. District Court for the Central District of California alleging the hedge fund attempted to extort the company “by misusing the inter partes review (IPR) process.” Ferrum filed an IPR in March with the U.S. Patent and Trademark Office challenging a claim on an Allergan patent covering Combigan 0.2% brimonidine/0.5% timolol solution on the grounds of obviousness.

Allergan is seeking a judgment that Ferrum Ferro’s use of the IPR process constitutes attempted civil extortion and malicious prosecution and violates California’s unfair competition law. The company also is requesting a permanent injunction prohibiting Ferrum Ferro from pursuing the IPR, an award for damages and a jury trial. ...